Skip to main content

NASDAQ:BIOL - BIOLASE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.58
  • Forecasted Upside: 125.29 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.70
▲ +0.12 (20.72%)
1 month | 3 months | 12 months
Get New BIOLASE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.58
▲ +125.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BIOLASE in the last 3 months. The average price target is $1.58, with a high forecast of $2.00 and a low forecast of $1.15. The average price target represents a 125.29% upside from the last price of $0.70.

Buy

The current consensus among 2 polled investment analysts is to buy stock in BIOLASE.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021Maxim GroupReiterated RatingBuy$2.00N/A
i
Rating by Anthony Vendetti at Maxim Group
3/26/2021Maxim GroupReiterated RatingBuy$2.00Low
i
3/8/2021Colliers SecuritiesReiterated RatingBuy$1.15High
i
1/26/2021Maxim GroupBoost Price TargetBuy$1.00 ➝ $2.00High
i
10/14/2020Maxim GroupInitiated CoverageBuy$1.00Low
i
8/12/2019Ascendiant Capital MarketsSet Price TargetBuy$3.00High
i
Rating by Ed Woo at Ascendiant Capital Markets
6/19/2019BenchmarkInitiated CoverageSpeculative Buy ➝ Speculative Buy$2.00High
i
4/30/2019Dougherty & CoReiterated RatingBuyHigh
i
Rating by K. Bauser at Dougherty & Co
3/7/2019Singular ResearchReiterated RatingBuyHigh
i
Rating by L. Springer at Singular Research
4/25/2017Singular ResearchInitiated CoverageBuy$12.50Low
i
(Data available from 5/16/2016 forward)
BIOLASE logo
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Read More

Today's Range

Now: $0.70
$0.67
$0.76

50 Day Range

MA: $0.78
$0.58
$1.02

52 Week Range

Now: $0.70
$0.25
$1.51

Volume

24,152,468 shs

Average Volume

22,945,693 shs

Market Capitalization

$105.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of BIOLASE?

The following equities research analysts have issued stock ratings on BIOLASE in the last twelve months: Colliers Securities, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for BIOL.

What is the current price target for BIOLASE?

2 Wall Street analysts have set twelve-month price targets for BIOLASE in the last year. Their average twelve-month price target is $1.58, suggesting a possible upside of 125.3%. Maxim Group has the highest price target set, predicting BIOL will reach $2.00 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $1.15 for BIOLASE in the next year.
View the latest price targets for BIOL.

What is the current consensus analyst rating for BIOLASE?

BIOLASE currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIOL will outperform the market and that investors should add to their positions of BIOLASE.
View the latest ratings for BIOL.

What other companies compete with BIOLASE?

How do I contact BIOLASE's investor relations team?

BIOLASE's physical mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company's listed phone number is 949-361-1200 and its investor relations email address is [email protected] The official website for BIOLASE is www.biolase.com.